Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089050 · ClinicalTrials.gov registry record · Phase 2
Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00089050 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center.
The verdict
NCT00089050, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Cyclosporine may increase the effectiveness of gemtuzumab ozogamicin by making cancer cells more sensitive to the drug. Combining gemtuzumab ozogamicin with cyclosporine may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving gemtuzumab ozogamicin together with cyclosporine works in treating older patients with relapsed acute myeloid leukemia.
Interventions
- DRUG cyclosporine
- DRUG gemtuzumab ozogamicin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-05 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00089050
The ClinicalTrials.gov registry entry for NCT00089050 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cyclosporine is the first listed.
NCT00089050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00089050 about?
NCT00089050 is a clinical study titled "Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia". RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Cyclosporine may increase the effectiveness of gemtuzumab ozogamicin by making cancer cells more sensitive to the dru...
What is the current status of trial NCT00089050?
This trial is currently completed. It is a Phase 2 study. The study started on 2004-05. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00089050?
The interventions under investigation include: cyclosporine (DRUG), gemtuzumab ozogamicin (DRUG).
Who is sponsoring clinical trial NCT00089050?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.